Longeveron Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Longeveron Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Miami
- Headquarters state / province
- Florida
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- LGVN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001721484
- EIN
- 47-2174146
Board of directors
-
Arjun Jj Desai · DirectorSince 2026
-
Cathy Ross · DirectorSince 2023
-
Deborah Ascheim · DirectorSince 2026
-
Douglas W. Losordo · DirectorSince 2023
-
George A. Paletta Jr. · DirectorSince 2025
-
Jeffrey Pfeffer · DirectorSince 2023
-
Joshua Hare · Director · Chief Scientific OfficerSince 2023
-
Khoso Baluch · DirectorSince 2023
-
Leah Rush Cann · DirectorSince 2026
-
Mohamed Wa'el Ahmed Hashad · Director · Chief Executive OfficerSince 2024
-
Neha J. Motwani · DirectorSince 2024
-
Neil E. Hare · DirectorSince 2023
-
Richard N. Kender · DirectorSince 2024
-
Rock Soffer · DirectorSince 2023
-
Roger Joseph Hajjar · DirectorSince 2024
-
Ursula Ungaro · DirectorSince 2023
Chief executives
Mohamed Wa'el Ahmed Hashad
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 13, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
96.1%
Board connections
4 of this board's directors also sit on 6 other boards.
- via Mohamed Wa'el Ahmed Hashad
- via Richard N. Kender
- via Arjun Jj Desai
- via Khoso Baluch
- via Richard N. Kender
- via Arjun Jj Desai
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Agafonova Nataliya Officer (Chief Medical Officer) | Grant or award | +286,000 | — | — |
| Aug 19, 2026 | Deborah Ascheim Director | Grant or award | +36,000 | — | — |
| Aug 19, 2026 | Blass Devin Officer (CTO & SVP of CMC) | Grant or award | +286,000 | — | — |
| Aug 19, 2026 | Leah Rush Cann Director | Grant or award | +36,000 | — | — |
| Aug 19, 2026 | Arjun Jj Desai Director | Grant or award | +36,000 | — | — |
| Aug 19, 2026 | Roger Joseph Hajjar Director | Grant or award | +36,000 | — | — |
| Aug 19, 2026 | Joshua Hare Director, Officer (Chief Scientific Officer), 10% owner | Grant or award | +286,000 | — | — |
| Aug 19, 2026 | Lehr Paul T Officer (General Counsel, Secretary) | Grant or award | +286,000 | — | — |
| Aug 19, 2026 | Ursula Ungaro Director | Grant or award | +36,000 | — | — |
| Aug 19, 2026 | George A. Paletta Jr. Director | Grant or award | +36,000 | — | — |
| Aug 19, 2026 | Rock Soffer Director | Grant or award | +36,000 | — | — |
| Aug 17, 2026 | Jhaveri Nirav S. Officer (Chief Financial Officer) | Grant or award | +300,000 | — | — |
| Jul 6, 2026 | Joshua Hare Director, Officer (Chief Scientific Officer), 10% owner | Grant or award | +600,000 | — | — |
| Jul 1, 2026 | Agafonova Nataliya Officer (Chief Medical Officer) | Shares withheld for tax | −22,505 | $0.73 | $16,408 |
| Jul 1, 2026 | Blass Devin Officer (CTO & SVP of CMC) | Shares withheld for tax | −15,808 | $0.73 | $11,526 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.